最新消息
News
首筆授權金挹注營收 漢康-KY聚焦2026年臨床與商務發展重點 推進HCB101臨床開發、創新板上市進程及國際合作布局 HanchorBio Reports First Licensing Revenue and Outlines 2026 Clinical and Business Development Priorities
HanchorBio today announced that its 2026 Annual General Meeting was successfully held on May 21, 2026, in Taipei, Taiwan. Shareholders approved all proposed resolutions, including the 2025 business report, financial statements, and loss offset proposal.
5 月 21, 2026
Read more
漢康-KY上市前業績發表會 5/11登場 FBDB核心平台構築抗癌護城河 瞄準千億美元商機 HanchorBio to Hold May 11 Investor Presentation Ahead of Planned Taiwan Innovation Board Listing
HanchorBio announced that it will hold an investor presentation on May 11 ahead of its planned listing on the Taiwan Innovation Board later this month.
5 月 08, 2026
Read more
漢康生技與彭博合作 強化藥物開發及全球生物製藥戰略情報能力 HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma
HanchorBio announced it has selected Bloomberg to support strategic decision-making across portfolio planning, pipeline development, competitive monitoring, business development, and capital markets activities.
4 月 24, 2026
Read more
HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering 漢康-KY獲證交所董事會通過股票創新板上市 核心技術FBDB™平台開發價值高
HanchorBio, Inc., a global clinical-stage biotechnology company advancing next-generation multifunctional biologics across oncology and immune-related diseases, today announced that it has received approval from the Board of Directors of the Taiwan Stock Exchange to list on the TWSE Innovation Board, with listing anticipated in the second quarter of 2026, subject to completion of the remaining customary procedures.
3 月 24, 2026
Read more
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline漢康生技攜手藥明生物，推進新一代雙/多功能融合蛋白平臺及多專案產品線開發
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.
致力於開發下一代免疫療法的全球臨床階段生物技術公司漢康生技與全球領先的CRDMO服務公司藥明生物共同宣佈，雙方簽署戰略合作協定，藥明生物將為漢康生技管線中多款新一代雙功能及多功能融合蛋白專案提供開發與生產服務。
1 月 26, 2026
Read more
漢康-KY完成抗癌藥HCB101授權簽署 推動癌症治療新標竿
專注於免疫腫瘤學創新生物藥開發的漢康-KY（7827）6月30日宣布，與上海復宏漢霖生物技術股份有限公司（以下 […]
6 月 30, 2025
Read more
莎多利斯攜手漢康生技簽訂合作意向書 聯手攻克創新癌藥CMC挑戰
6月27日，國際領先的生命科學集團莎多利斯(Sartorius)宣布，與全球性生技新藥開發公司漢康生技(HanchorBio)簽訂合作意向書，藉由莎多利斯在生物藥製程的先進解決方案，與漢康生技在複雜分子構型蛋白藥開發核心技術的整合，共同克服化學製造與管制(CMC)挑戰。漢康生技也成為莎多利斯在臺灣地區第一個簽訂合作意向書的生技新藥開發公司。
7 月 08, 2024
Read more